natgillin/translations-raw huggingface dataset:
RSV hospitalisations occurred among 62 of 3306 (1.9%) patients in the palivizumab group. 
Hospitalizacija zbog RSV-a dogodila se u 62 od 3306 bolesnika (1,9%) u skupini koja je dobivala palivizumab.
1 ml Water for injections 
1 ml vode za injekcije
The incidence of infection PSAEs was lower in children who received prophylaxis as compared to those children who did not receive prophylaxis. 
Incidencija infekcije bila je niža u djece koja su primila profilaksu u usporedbi s djecom koja profilaksu nisu primila.
Palivizumab should be given with caution to patients with thrombocytopaenia or any coagulation disorder. 
Palivizumab treba davati oprezno bolesnicima s trombocitopenijom ili poremećajima koagulacije.
In a genotypic analysis of 126 clinical isolates from 123 children who failed immunoprophylaxis, all RSV mutants that exhibited resistance to palivizumab (n=8) were shown to contain amino acid changes in this region of the F protein. 
U genotipskoj analizi 126 kliničkih izolata prikupljenih u 123 djece u kojih imunoprofilaksa nije bila uspješna, pokazalo se da svi mutanti RSV-a koji su pokazivali rezistenciju na palivizumab (n=8) imaju promjene na aminokiselinama u tom području F proteina.
The RSV hospitalisation rate observed in patients enrolled with a diagnosis of CLDP was 28/723 (3.9%) and in patients enrolled with a diagnosis of prematurity without CLDP was 34/2583 (1.3%). 
Stopa hospitalizacije zbog RSV-a kod bolesnika koji su imali dijagnozu CLDPa prilikom ulaska u studiju bila je 28/723 (3,9%), a kod nedonoščadi bez CLDP-a prilikom ulaska u studiju bila je 34/2583 (1,3%).
Synagis is a medicine to help protect your child from getting severe RSV illness. 
Synagis je lijek koji će pomoći zaštititi Vaše dijete od dobivanja teške bolesti uzrokovane RSV-om.
Synagis Water for injections ampoule label 
Synagis voda za injekciju naljepnica na ampuli
Anaphylaxis, anaphylactic shock (in some cases, fatalities have been reported.) 
Poremećaji imunološkog sustava nepoznato anafilaksija, anafilaktički šok (u nekim slučajevima prijavljen je smrtni ishod)
Synagis solution for injection is a clear or slightly opalescent solution and is available in vials of either 0.5 ml or 1 ml. 
Synagis otopina za injekciju je bistra ili blago opalescentna otopina i dostupna je u bočicama od 0,5 ml ili 1 ml.
Palivizumab exhibited median EC50 values of 0.65 g/ml (mean [standard deviation] = 0.75 [0.53] g/ml; n=69, range 0.07-2.89 g/ml) and 0.28 g/ml (mean [standard deviation] = 0.35 [0.23] g/ml; n=35, range 0.03-0.88 g/ml) against clinical RSV A and RSV B isolates, respectively. 
Medijan EC50 vrijednosti palivizumaba protiv kliničkih izolata RSV A iznosio je 0,65 µg/ml (srednja vrijednost [standardno odstupanje] = 0,75 [0,53] µg/ml; n=69, raspon: 0,07-2,89 µg/ml), a protiv izolata RSV B 0,28 µg/ml (srednja vrijednost [standardno odstupanje] = 0,35 [0,23] µg/ml; n=35, raspon: 0,03-0,88 µg/ml).
Insert the needle into the vial and withdraw into the syringe an appropriate volume of solution. 
Umetnuti iglu u bočicu te uvući odgovarajući volumen otopine u štrcaljku.
Adverse reactions observed in patients after a sixth or greater dose were similar in character and frequency to those after the initial 5 doses. 
Nuspojave zabilježene u bolesnika nakon šeste ili kasnije doze bile su po svojim karakteristikama i učestalosti slične onima zabilježenima nakon prvih 5 doza.
For children undergoing cardiac bypass, it is recommended that a 15 mg/kg of body weight injection of palivizumab be administered as soon as stable after surgery to ensure adequate palivizumab serum levels. 
Djeci podvrgnutoj operaciji ugradnje srčanih premosnica preporučuje se dati injekciju palivizumaba od 15 mg/kg tjelesne težine čim se postoperativno stanje stabilizira kako bi se održale odgovarajuće serumske koncentracije palivizumaba.
The RSV hospitalisation rate was 10.6% in the placebo group. 
Postotak hospitalizacija zbog RSV-a u skupini na placebu bio je 10,6%.
The incidence of arrhythmia and death PSAEs was similar in children who did and did not receive prophylaxis. 
Incidencija aritmije i smrti bila je slična u djece koja jesu i one koja nisu primila profilaksu.
Palivizumab may interfere with immune-based RSV diagnostic tests, such as some antigen detection based assays. 
Palivizumab može utjecati na imunološke testove za dijagnosticiranje RSV-a, poput nekih testova koji se temelje na detekciji antigena.
Name and address of the manufacturer(s) of the biological active substance 
Naziv(i) i adresa(e) proizvođača biološke djelatne tvari
Groups were equally balanced between cyanotic and acyanotic patients. 
Skupine su bile slične s obzirom na broj cijanotičnih i necijanotičnih bolesnika.
In the second study, 211 and 202 premature infants or children with chronic lung disease received liquid and lyophilised palivizumab, respectively. 
U drugom ispitivanju je 211 nedonoščadi ili djece s kroničnom plućnom bolesti dobivalo tekući, a 202 liofilizirani palivizumab.
Ltd Τηλ: +357 22 34 74 40 
Lifepharma (Z.A.M.) Ltd Τηλ.: +357 22 34 74 40
The solution is clear or slightly opalescent. 
Otopina je bistra ili blago opalescentna.
*For full study description, see Section 5.1 Clinical studies # ADRs identified from post-marketing surveillance 
* Za cjeloviti opis ispitivanja vidjeti dio 5.1 'Klinička ispitivanja' # Nuspojave identificirane na temelju praćenja nakon stavljanja lijeka u promet
In two additional studies, liquid palivizumab was used as an active control (3918 pediatric subjects) to evaluate an investigational monoclonal antibody for prophylaxis of serious RSV disease in premature infants or children with BPD or hemodynamically significant CHD (see below for further details of these two studies). 
U dva dodatna ispitivanja tekući palivizumab je korišten kao aktivna kontrola (3918 pedijatrijskih ispitanika) radi ocjene ispitivanog monoklonskog protutijela u profilaksi ozbiljne bolesti uzrokovane RSV-om u nedonoščadi ili djece s bronhopulmonalnom displazijom ili hemodinamski značajnom kongenitalnom bolesti srca (dodatne pojedinosti ova dva ispitivanja vidjeti u nastavku).
Single-use vials: 3 ml capacity, clear, colourless type I glass vial with a chlorobutyl stopper and flipoff seal containing either 0.5 ml or 1 ml of solution for injection. 
Bočice za jednokratnu uporabu: bočica od 3 ml, od prozirnog, bezbojnog stakla tipa I, s klorobutil čepom i „flip-off“ zatvaračem koja sadrži 0,5 ml ili 1 ml otopine za injekcije.
However, as the efficacy of palivizumab when administered to patients as a second course of treatment during an ensuing RSV season has not been formally investigated in a study performed with this objective, the relevance of these data in terms of efficacy is unknown. 
No, s obzirom da djelotvornost palivizumaba primijenjenog bolesnicima po drugi put tijekom sljedeće sezone RSV-a nije formalno istraživana u ispitivanju s tako postavljenim ciljem, relevantnost ovih podataka za procjenu djelotvornosti nije poznata.
Palivizumab serum concentrations of approximately 30 g/ml have been shown to produce a 99% reduction in pulmonary RSV replication in the cotton rat model. 
Pri serumskim koncentracijama od približno 30 g/ml palivizumab smanjuje replikaciju RSV-a u plućima štakora za 99% (cotton rat model).
(3 x 0.15) ml = 0.45 ml palivizumab per month 
(3 x 0,15) ml = 0,45 ml palivizumaba mjesečno
No deaths were considered related to palivizumab and no new ADRs were identified in these studies. 
Smatra se da smrtni ishodi nisu povezani s primjenom palivizumaba te u ovim ispitivanjima nisu zabilježene nove nuspojave.
*Palivizumab is a recombinant humanised monoclonal antibody produced by DNA technology in mouse myeloma host cells. 
*palivizumab je rekombinantno humanizirano monoklonsko antitijelo proizvedeno DNA tehnologijom u stanicama domaćina mišjeg mijeloma.
A moderate to severe acute infection or febrile illness may warrant delaying the use of palivizumab, unless, in the opinion of the physician, withholding palivizumab entails a greater risk. 
Umjerena do teška akutna infekcija ili febrilna bolest može opravdati odgađanje primjene palivizumaba, osim ako liječnik ne procijeni da odgađanje primjene palivizumaba predstavlja još veći rizik.
1ml of water for injections in an ampoule (type I glass). 
1 ml vode za injekciju u ampuli (staklo tip I).
Nervous system disorders Uncommon 
Poremećaji živčanog sustava manje često konvulzije
Additional side effects Very common (affects at least 1 user in 10): rash fever 
Dodatne nuspojave Vrlo često (javlja se u najmanje 1 korisnika na 10): osip vrućica
A review of clinical findings did not reveal an association between A antigenic site sequence changes and RSV disease severity among children receiving palivizumab immunoprophylaxis who develop RSV lower respiratory tract disease. 
Ocjena kliničkih nalaza nije otkrila asocijaciju između promjena na sekvenci antigenskog mjesta A i težine RSV bolesti u djece koja su primila imunoprofilaksu palivizumabom i razvila RSV-om uzrokovanu bolest donjeg dišnog sustava.
Palivizumab treatment schedule and adverse reactions were monitored in a group of nearly 20,000 infants tracked through a patient compliance registry between 1998 and 2000. 
Raspored primjene palivizumaba i nuspojave promatrani su u skupini od gotovo 20 000 dojenčadi koja su praćena kroz registar suradljivosti bolesnika između 1998. i 2000. godine.
• Children born at 35 weeks of gestation or less and less than 6 months of age at the onset of the RSV season 
• Djeca rođena u 35. tjednu trudnoće ili ranije i koja su na početku sezone RSV-a bila mlađa od 6
The antiviral activity of palivizumab was assessed in a microneutralization assay in which increasing concentrations of antibody were incubated with RSV prior to addition of the human epithelial cells HEp-2. 
Protuvirusno djelovanje palivizumaba ispitano je u testu mikroneutralizacije u kojem je izvršena inkubacija rastućih koncentracija anitijela RSV-om, a zatim su dodane humane epitelne stanice HEp-2.
- The other ingredients are histidine, glycine and water for injections. 
- Drugi sastojci su histidin, glicin i voda za injekcije.
Always use this medicine exactly as your doctor or pharmacist has told you. 
Uvijek primijeniteovaj lijek točno onako kako Vam jerekaoliječnikililjekarnik.
How will my child receive Synagis 
Kako će moje dijete primiti Synagis
1 ampoule 1 ml water for injections. 
1 ampula s 1 ml vode za injekcije.
How will my child receive Synagis? 
Kako će moje dijete primiti Synagis?
Also contains: histidine, glycine and water for injections. 
Također sadrži: histidin, glicin i vodu za injekcije.
100 mg of powder in a 10 ml vial (type I glass) with a stopper (butyl rubber) and a flip-off seal (aluminium). 
100 mg praška u bočici od 10 ml (staklo tip I) sa čepom (butil guma) i sa „flip-off“ zatvaračem (aluminij).
Τηλ: +30 214 4165 555 
AbbVie ΦΑΡΜΑΚΕΥΤΙΚΗ Α.Ε. Τηλ: + 30 214 4165 555
The possible risk of enhanced RSV infection in the season following the season in which the patients were treated with palivizumab has not been conclusively ruled out by studies performed aiming at this particular point. 
Mogućnost povećanog rizika infekcije RSV-om u sezoni nakon one u kojoj je bolesnik primao palivizumab nije izričito isključena ispitivanjima koja su provedena s tim ciljem.
Your child can then go back to the original planned injection. 
Nakon toga treba nastaviti s primanjem injekcija prema prvobitno propisanom rasporedu.
50 mg of powder in a 4 ml vial (type I glass) with a stopper (butyl rubber) and a flip-off seal (aluminium). 
50 mg praška u bočici od 4 ml (staklo tip I) sa čepom (butil guma) i sa „flip-off“ zatvaračem (aluminij).
Transient, low levels of antipalivizumab antibody were observed in one child after the second dose of palivizumab that dropped to undetectable levels at the fifth and seventh dose. 
U jednog su djeteta nakon druge doze palivizumaba pronađene prolazne niske razine antitijela protiv palivizumaba koja su se nakon pete i sedme doze smanjila na razine koje se više ne mogu otkriti.
In this trial, patients were randomized to receive 5 monthly injections of 15mg/kg of liquid palivizumab (N=612) used as active control for an investigational monoclonal antibody (N=624). 
U ovom ispitivanju bolesnici su randomizirani i dobivali su 5 mjesečnih injekcija od 15 mg/kg tekućeg palivizumaba (N=612) kao aktivnu kontrolu ispitivanom monoklonskom protutijelu (N=624).
(3 x 0.15) ml = 0.45 ml palivizumab per month. 
(3 x 0,15) ml = 0,45 ml palivizumaba mjesečno.
Palivizumab is a humanised IgG1 monoclonal antibody directed to an epitope in the A antigenic site of the fusion protein of respiratory syncytial virus (RSV). 
Palivizumab je humanizirano IgG1 monoklonsko antitijelo usmjereno protiv epitopa na A antigenskom mjestu fuzijskog proteina respiracijskog sincicijskog virusa (RSV).
Antibody to palivizumab was evaluated in four additional studies in 4337 patients (children born at 35 weeks of gestation or less and 6 months of age or less, or 24 months of age or less with bronchopulmonary dysplasia, or with haemodynamically significant congenital heart disease were included in these studies) and was observed in 0% - 1.5% of patients at different study timepoints. 
Antitijela na palivizumab ocijenjena su u četiri dodatna ispitivanja u 4337 bolesnika (u ta ispitivanja su bila uključena djeca rođena u 35. tjednu gestacije ili ranije koja su pri uključivanju imala 6 mjeseci ili manje, ili djeca u dobi od 24 mjeseca ili manje s bronhopulmonalnom displazijom ili hemodinamski značajnom kongenitalnom bolešću srca), a zabilježena su u 0% - 1,5% bolesnika u različitim vremenskim točkama tijekom ispitivanja.
The incidences of these reactions in these studies showed no difference between the palivizumab and placebo groups and the reactions were not drug related. 
Incidencija navedenih nuspojava u tim ispitivanjima nije se razlikovala između skupina koje su primale palivizumab odnosno placebo, a nuspojave nisu bile uzročno povezane s primjenom lijeka.
What do you need to know before Synagis is given to your child 
Što morate znati prije nego vaše dijete primi Synagis
Secondary efficacy endpoints showed significant reductions in the Synagis group compared to placebo in total days of RSV hospitalisation (56% reduction, p = 0.003) and total RSV days with increased supplemental oxygen (73% reduction, p = 0.014) per 100 children. 
Sekundarne mjere ishoda djelotvornosti pokazale su značajno smanjenje u skupini liječenoj lijekom Synagis u usporedbi sa skupinom na placebu u ukupnim danima trajanja hospitalizacije zbog RSV-a (smanjenje 56%, p = 0,003) te ukupnim brojem dana s dodatnom opskrbom kisikom tijekom bolesti uzrokovane RSV-om na 100 djece (smanjenje 73%, p = 0,014).
In this trial, patients were randomized to receive 5 monthly injections of 15mg/kg of liquid palivizumab (N=3306) used as active control for an investigational monoclonal antibody (N=3329). 
U ovom ispitivanju bolesnici su randomizirani i dobivali su 5 mjesečnih injekcija od 15 mg/kg tekućeg palivizumaba (N=3306) kao aktivnu kontrolu ispitivanom monoklonskom protutijelu (N=3329).
Both the 0.5 ml and 1 ml vials contain an overfill to allow the withdrawal of 50 mg or 100 mg, respectively. 
Bočice od 0,5 ml i 1 ml sadrže suvišak kako bi se omogućilo izvlačenje 50 mg odnosno 100 mg lijeka.
Pre-term infants and children with Chronic Lung Disease of Prematurity (CLDP): this trial, conducted at 347 centers in the North America, European Union and 10 other countries, studied patients less than or equal to 24 months of age with CLDP and patients with premature birth (less than or equal to 35 weeks gestation) who were less than or equal to 6 months of age at study entry. 
Nedonoščad i djeca s kroničnom plućnom bolesti zbog prematuriteta (engl. chronic lung disease of prematurity, CLDP): u ovom ispitivanju, provedenom u 347 centara u Sjevernoj Americi, Europskoj Uniji i 10 ostalih zemalja, proučavani su bolesnici od 24 mjeseca ili mlađi s CLDP-om i prijevremeno rođeni bolesnici (35 tjedana gestacije ili ranije) koji su bili u dobi od 6 mjeseci ili mlađi prilikom ulaska u studiju.
In an observational, post-marketing, database study, a small increase in the frequency of asthma was observed among preterm palivizumab recipients; however, the causal relationship is uncertain. 
U opservacijskom ispitivanju prikupljenih podataka nakon stavljanja lijeka u promet zabilježeno je malo povećanje učestalosti astme u prijevremeno rođenih bolesnika koji su primali palivizumab, međutim uzročno posljedična veza nije jasna.
In the phase III IMpactRSV study in the premature and bronchopulmonary dysplasia paediatric populations, the proportions of patients in the placebo and palivizumab groups who received routine childhood vaccines, influenza vaccine, bronchodilators or corticosteroids were similar and no incremental increase in adverse reactions was observed among patients receiving these agents. 
U ispitivanju faze III IMpactRSV u nedonoščadi i djece s bronhopulmonalnom displazijom, postotak bolesnika koji su dobivali uobičajena dječja cjepiva, cjepivo protiv gripe, bronhodilatatore ili kortikosteroide bio je sličan u skupinama liječenim placebom i palivizumabom i nije zabilježeno povećanje učestalosti nuspojava u bolesnika koji su uzimali navedene lijekove.
Do not dilute the product. 
Ne razrjeđujte lijek.
Palivizumab binds a highly conserved region on the extracellular domain of mature RSV F protein, referred to as antigenic site II or A antigenic site, which encompasses amino acids 262 to 275. 
Palivizumab se veže za dobro očuvano područje na izvanstaničnoj domeni zrelog proteina RSV F, koje se naziva antigenskim mjestom II ili antigenskim mjestom A, a obuhvaća aminokiseline 262 do 275.
Mannitol (E421) 
Prašak: histidin glicin manitol (E421)
In an open label prospective trial designed to evaluate pharmacokinetics, safety and immunogenicity after administration of 7 doses of palivizumab within a single RSV season, pharmacokinetic data indicated that adequate mean palivizumab levels were achieved in all 18 children enrolled. 
U prospektivnom otvorenom ispitivanju osmišljenom za istraživanje farmakokinetike , sigurnosti i imunogenosti nakon primjene 7 doza palivizumaba unutar jedne sezone RSV-a, farmakokinetički podaci pokazali su da su u sve 18 uključene djece postignute odgovarajuće srednje razine palivizumaba.
Reconstitute slowly with 0.6 ml water for injections. 
Pripremiti polako s 0,6 ml vode za injekcije.
Analysis of 254 clinical RSV isolates collected from immunoprophylaxis-naïve subjects revealed palivizumab resistance-associated substitutions in 2 (1 with N262D and 1 with S275F), resulting in a resistance associated mutation frequency of 0.79%. 
Analiza 254 klinička izolata RSV-a prikupljena u ispitanika koji nikada nisu primili imunoprofilaksu otkrila je supstitucije povezane s rezistencijom na palivizumab u 2 slučaja (jedan N262D i jedan S275F), što čini učestalost mutacija povezanih s rezistencijom od
Powder and solvent for solution for injection Contents: 
Prašak i otapalo za otopinu za injekciju Sadržaj:
This medicinal product should not be mixed with other medicinal products or diluents other than water for injections. 
Lijek se ne smije miješati s drugim lijekovima ili otapalima osim s vodom za injekcije.
Among 139 children in the congenital heart disease study receiving palivizumab who had cardio-pulmonary bypass and for whom paired serum samples were available, the mean serum palivizumab concentration was approximately 100 g/ml pre-cardiac bypass and declined to approximately 40 g/ml after bypass. 
U ispitivanju kongenitalne bolesti srca kod 139 djece koja su primala palivizumab i koja su podvrgnuta operaciji ugradnje srčanih premosnica i za koje su bili dostupni parni uzorci seruma, srednja serumska koncentracija palivizumaba bila je približno 100 μg/ml prije ugradnje srčanih premosnica, a smanjila se na približno 40 μg/ml nakon premosnica.
Solution for injection 100 mg/1 ml 
Otopina za injekciju 100 mg/1 ml
Please tell your doctor if your child is unwell, as the use of Synagis may need to be delayed. 
Recite liječniku ako Vaše dijete nije dobro jer će možda trebati odgoditi primjenu lijeka Synagis. ako Vaše dijete ima poremećaje krvarenja jer se Synagis obično ubrizgava u bedro.
Palivizumab should not be mixed with any medicinal products or diluents other than water for injections. 
Palivizumab se ne smije miješati s drugim lijekovima ili otapalima osim s vodom za injekcije.
How often will Synagis be given to my child? 
Koliko puta će moje dijete primiti Synagis?
In prophylactic studies in premature and bronchopulmonary dysplasia paediatric populations, the mean half-life of palivizumab was 20 days and monthly intramuscular doses of 15 mg/kg achieved mean 30 day trough serum active substance concentrations of approximately 40 g/ml after the first injection, approximately 60 g/ml after the second injection, approximately 70 g/ml after the third injection and fourth injection. 
U profilaktičkim ispitivanjima u nedonoščadi i djece s bronhopulmonalnom displazijom, poluvrijeme eliminacije palivizumaba bilo je u prosjeku 20 dana, a mjesečnim intramuskularnim dozama od 15 mg/kg postignute najniže srednje serumske koncentracije djelatne tvari u 30-dnevnom razdoblju bile su približno 40 μg/ml nakon prve injekcije, približno 60 μg/ml nakon druge injekcije i približno 70 μg/ml nakon treće i četvrte injekcije.
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTUR ER(S) RESPONSIBLE FOR BATCH RELEASE 
PROIZVOĐAČ(I) BIOLOŠKE(IH) DJELATNE(IH) TVARI I PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
Also contains histidine, glycine and mannitol. 
Također sadrži histidin, glicin i manitol.
Boehringer Ingelheim Pharma GmbH & Co. KG D-88397 Biberach an der Riss Germany 
KG D-88397 Biberach an der Riss Njemačka
The pharmacokinetics and safety of palivizumab liquid formulation and palivizumab lyophilised formulation, following 15 mg/kg intramuscular administration, were compared in a cross-over trial of 153 infants less than or equal to 6 months of age with a history of prematurity (less than or equal to 35 weeks gestational age). 
U ukriženom ispitivanju uspoređivane su farmakokinetika i sigurnost tekućeg i liofiliziranog oblika palivizumaba nakon intramuskularne primjene doze od 15 mg/kg u 153 dojenčadi u dobi od 6 mjeseci ili mlađe rođene prijevremeno (35 tjedana gestacije ili ranije).
Adverse reactions both clinical and laboratory, are displayed by system organ class and frequency (very common ≥ 1/10; common ≥ 1/100 to < 1/10; uncommon ≥ 1/1,000 to < 1/100; rare ≥ 1/10,000 to <1/1,000 ) in studies conducted in premature and bronchopulmonary dysplasia paediatric patients, and paediatric congenital heart disease patients. 
Nuspojave, i kliničke i laboratorijske, razvrstane su prema organskom sustavu i učestalosti (vrlo često ≥ 1/10; često ≥1/100 i <1/10; manje često ≥1/1000 i <1/100; rijetko ≥ 1/10 000 i < 1/1000) u studijama provedenim kod nedonoščadi i djece s bronhopulmonalnom displazijom te djece s kongenitalnom bolesti srca.
Palivizumab does not interfere with reverse transcriptase polymerase chain reaction-based assays. 
Palivizumab ne utječe na testove lančane reakcije polimeraze nakon reverzne transkripcije.
1 vial Synagis 100 mg. 
1 bočica Synagis 100 mg.
The efficacy of palivizumab when administered to patients as a second course of treatment during an ensuing RSV season has not been formally investigated in a study performed with this objective. 
Djelotvornost palivizumaba u bolesnika koji bi ga primili u drugom ciklusu tijekom sljedeće sezone RSV infekcija nije formalno ispitana u istraživanju s tako postavljenim ciljem.
CHD Study 2: this trial, conducted at 162 centers in North America, European Union and 4 other countries over two RSV seasons, studied patients less than or equal to 24 months of age with hemodynamically significant CHD. 
Kongenitalna bolest srca Ispitivanje 2: u ovom ispitivanju, provedenom u 162 centra u Sjevernoj Americi, Europskoj Uniji i 4 ostale zemlje tijekom 2 sezone RSV-a, proučavani su bolesnici od 24 mjeseca ili mlađi s hemodinamski značajnom kongenitalnom bolesti srca.
Uncommon (affects less than 1 user in 100): fits hives 
Manje često (javlja se u manje od 1 korisnika na 100): napadaji koprivnjača
How to store Synagis 
Kako čuvati Synagis